Drug Trial Radar · NCT04732494
Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Last checked: Nov 19, 2026Latest source record: Jan 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
125
Actual
Start
Mar 31, 2021
Primary completion
Feb 1, 2023
Study completion Dec 26, 2023
Sponsor
- Lead sponsor
- BeiGeneBeOne Medicines (BeiGene) (ONC)
- Sponsor type
- Industry
- First posted
- Feb 1, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study of tislelizumab (BGB-A317) plus ociperlimab versus tislelizumab plus placebo as second-line treatment in participants with programmed cell death protein-ligand 1 (PD-L1) tumor area positivity (TAP) ≥ 10% unresectable, locally advanced, recurrent or metastatic esophageal squamous cell carcinoma.
Conditions
- Esophageal Squamous Cell Carcinoma
Interventions
TislelizumabBiological
Tislelizumab is a monoclonal antibody formulated for intravenous injection.
OciperlimabBiological
Ociperlimab is a monoclonal antibody formulated for intravenous injection.
PlaceboDrug
Ociperlimab placebo injection is a sterile, preservative-free solution for infusion formulated in the same buffer as ociperlimab active drug.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) Assessed by the InvestigatorTime frame: Up to the primary analysis data cutoff date of 01 February 2023; median (range) time on follow-up was 7.4 (0.5 - 20.1) months in Arm A and 6.4 (0.4 - 20.2) months in Arm B.
Locations
86 sites in 6 countries. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, China
Beijing Friendship Hospital, Capital Medical University
Beijing, China
Heping Hospital Affiliated to Changzhi Medical College
Changzhi, China
The First People's Hospital of Changzhou
Changzhou, China
Fujian Cancer Hospital
Fujian, China
The First Affiliated Hospital of Fujian Medical University
Fujian, China
Zhongshan Hospital Xiamen University
Fujian, China
Cancer Hospital of Shantou University Medical College
Guangdong, China
Nanfang Hospital of Southern Medical University
Guangdong, China
Sun Yat-sen University Cancer Center
Guangdong, China
The First Affiliated Hospital of Guangzhou University of Chinese Medicine
Guangdong, China
The Sixth Affiliated Hospital, Sun Yat-sen University
Guangdong, China
Guangxi Medical University Affiliated Tumor Hospital
Guangxi, China
Hainan General Hospital
Hainan, China
Affiliated Hospital of Hebei University
Hebei, China
The Second Hospital of Anhui Medical University
Hefei, China
Harbin Medical University Cancer Hospital
Heilongjiang, China
Henan Cancer Hospital
Henan, China
The First Affiliated Hospital of Xinxiang Medical University
Henan, China
The First Affiliated Hospital of Zhengzhou University
Henan, China
Hubei Cancer Hospital
Hubei, China
Xiangyang Central Hospital
Hubei, China
Hunan Cancer Hospital
Hunan, China
The First Affiliated Hospital of Nanchang University
Jiangxi, China
The Second Affiliated Hospital of Nanchang University
Jiangxi, China
Linyi Cancer Hospital
Shandong, China
Weifang People's Hospital
Shandong, China
Shanghai Chest Hospital
Shanghai, China
Liaoning Cancer Hospital & Institute
Shenyang, China
Sichuan Provincial People's Hospital
Sichuan, China
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, China
Northern Jiangsu People's Hospital
Yangzhou, China
Hangzhou Cancer Hospital
Zhejiang, China
Hwa Mei Hospital, University of Chinese Academy of Sciences
Zhejiang, China
Anhui Provincial Cancer Hospital
Hefei, Anhui, China
Quanzhou First Hospital of Fujian Province
Quanzhou, Fujian, China
First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China
Lanzhou University Second Hospital
Gansu, Gansu, China
Guangdong Provincial Hospital of Chinese Medicine
Guangzhou, Guangdong, China
Meizhou Hospital Affiliated to Sun Yat-sen University
Guangzhou, Guangdong, China
Showing 40 of 86 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.